Researchers have developed a one-time injection that produces lasting reductions in LDL cholesterol, the harmful form linked to heart disease and stroke. In a recent clinical trial, the treatment slashed LDL levels by 62 percent in patients who received it.
The drug works by targeting a specific gene responsible for producing proteins that regulate cholesterol metabolism. After a single injection, patients experience sustained benefits without needing repeat doses or daily pills. This represents a fundamentally different approach from statins, the current standard treatment that requires lifelong daily use.
The trial demonstrated that the genetic modification created durable effects. Participants maintained dramatically lower cholesterol levels months after receiving the injection, suggesting the body's cells continue producing the beneficial protein change long-term.
High cholesterol affects roughly one in five American adults and accelerates plaque buildup in arteries, narrowing blood vessels and restricting blood flow to the heart and brain. Current treatments with statins reduce LDL by 20 to 55 percent, depending on the drug and dose. A 62 percent reduction approaches the effectiveness of injectable PCSK9 inhibitors, which cost thousands of dollars annually and require frequent administration.
The one-time injection addresses two major barriers to cholesterol management. Many patients struggle with medication adherence, missing doses or stopping treatment entirely. Others experience statin side effects including muscle pain and cognitive issues. A permanent fix eliminates both problems.
The approach uses a modified virus to deliver genetic instructions into liver cells. Once there, these cells produce more of a specific protein that removes cholesterol from the bloodstream. The modification persists as cells naturally replicate, maintaining the effect indefinitely.
Researchers still need to complete additional trials to establish long-term safety and determine optimal dosing. Questions remain about whether the treatment works equally well across different populations and whether any delayed side effects emerge years after injection.
If approved,